| Literature DB >> 28261155 |
Justin T Smith1, Andrew D Schneider1, Karina M Katchko1, Chawon Yun1, Erin L Hsu1.
Abstract
Chemokines play an important role in normal bone physiology and the pathophysiology of many bone diseases. The recent increased focus on the individual roles of this class of proteins in the context of bone has shown that members of the two major chemokine subfamilies-CC and CXC-support or promote the formation of new bone and the remodeling of existing bone in response to a myriad of stimuli. These chemotactic molecules are crucial in orchestrating appropriate cellular homing, osteoblastogenesis, and osteoclastogenesis during normal bone repair. Bone healing is a complex cascade of carefully regulated processes, including inflammation, progenitor cell recruitment, differentiation, and remodeling. The extensive role of chemokines in these processes and the known links between environmental contaminants and chemokine expression/activity leaves ample opportunity for disruption of bone healing by environmental factors. However, despite increased clinical awareness, the potential impact of many of these environmental factors on bone-related chemokines is still ill defined. A great deal of focus has been placed on environmental exposure to various endocrine disruptors (bisphenol A, phthalate esters, etc.), volatile organic compounds, dioxins, and heavy metals, though mainly in other tissues. Awareness of the impact of other less well-studied bone toxicants, such as fluoride, mold and fungal toxins, asbestos, and chlorine, is also reviewed. In many cases, the literature on these toxins in osteogenic models is lacking. However, research focused on their effects in other tissues and cell lines provides clues for where future resources could be best utilized. This review aims to serve as a current and exhaustive resource detailing the known links between several classes of high-interest environmental pollutants and their interaction with the chemokines relevant to bone healing.Entities:
Keywords: bone healing; chemokines; dioxin; endocrine disruptors; environmental toxins; metal; volatile organic compound
Year: 2017 PMID: 28261155 PMCID: PMC5306137 DOI: 10.3389/fendo.2017.00022
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Endocrine disruptors: chemokine changes.
| Substance | Chemokine(s) involved | Effect(s) | Cell/tissue type | Reference | |
|---|---|---|---|---|---|
| BPA | CXCL2 | ↓ | Mouse mammary gland | Fischer et al. ( | |
| CXCL12 | ↑ | Human BG-1 | Hall and Korach ( | ||
| Human MCF-7 and T47D | Habauzit et al. ( | ||||
| Human ECC-1 and T47D | Gertz et al. ( | ||||
| BPAF | CXCL12 | ↑ | Human T47D | Li et al. ( | |
| DEHP | ↑ | Human THP-1 | Nishioka et al. ( | ||
| CCL2 | ↓ | Mouse hypothalamus tissue | Win-Shwe et al. ( | ||
| DINP | CCL2 | ↓ | Mouse hypothalamus tissue | Win-Shwe et al. ( | |
| PFAS | CCL2 | No changes observed | Human serum | Stein et al. ( | |
| CCL3 | |||||
Known effects of endocrine disruptors on chemokines (BPA, bisphenol A; BPAF, bisphenol AF; DEHP, di-(2-ethylhexyl)-phthalate; DINP, di-isononyl-phthalate; PFAS, perfluoroalkyl substance).
Volatile organic compounds (VOCs): chemokine changes.
| Substance | Chemokine(s) involved | Effect(s) | Cell/tissue type | Reference |
|---|---|---|---|---|
| Benzene | CXCL12 | ↑ 1 h after exposure to 1,4-benzoquinone | Human mesenchymal stem cell | Zolghadr et al. ( |
| ↓ 24 h after exposure to hydroquinone | ||||
| CXCL8 | ↑ | Human PBMC and plasma | Gillis et al. ( | |
| Chlorobenzene | CCL2 | ↑ Indoor-relevant concentrations | Human PBMC and A549 | Lehmann et al. ( |
| Human A549 | Fischader et al. ( | |||
| ↓ High concentrations | Human A549 | Fischader et al. ( | ||
| m-Xylene and styrene | CCL2 | ↑ Indoor-relevant concentrations | Human A549 | Fischader et al. ( |
| ↓ High concentrations | ||||
| Other aliphatic compounds | CXCL8 | No change | Human A549 | Fischader et al. ( |
Known effects of VOCs on chemokines. Other aliphatic compounds refer to: n-non-ane, n-decane, n-undecan, n-dodecane, n-tridecane, and methylcyclopentane.
Dioxin and dioxin-like compounds: chemokine changes.
| Substance | Chemokine(s) involved | Effect(s) | Cell/tissue type | Reference |
|---|---|---|---|---|
| TCDD | CXCR4 | ↓ Migration | ||
| CXCL12 | ↑ | Mouse HSC | Casado et al. ( | |
| ↓ | ||||
| ↑ | Mouse thymus, liver, kidney, adipose, and cardiac tissue | Vogel et al. ( | ||
| CXCL1 | ↑ | Mouse peritoneal B1 cells | Ishikawa ( | |
| CXCL8 | Human MCF-7 | Monteiro et al. ( | ||
| CXCL12 | Human synovial tissue | Kobayashi et al. ( | ||
| CXCL13 | Mouse thymus, liver, kidney, adipose, and cardiac tissue | Vogel et al. ( | ||
| CCL1 | Human MCF-7 | |||
| Human synovial tissue | ||||
| CCL5 | ↓ | Mouse CD4+ T-cells | Marshall et al. ( | |
| PCB-126 | CXCL8 | ↑ | Porcine endothelial cells | Majkova et al. ( |
| CXCL13 | ||||
| CCL1 | Human NHEK | Tsuji et al. ( | ||
| CCL2 | ||||
| PCB-77 | Primary human macrophages | N’Diaye et al. ( | ||
| BaP | Human HaCaT and NHEK, mouse keratinocytes | Morino-Koga et al. ( | ||
| BaP | ↓ | Human HaCaT and NHEK, mouse keratinocytes | Morino-Koga et al. ( | |
| No change | ||||
Known effects of dioxin and dioxin-like compounds on chemokines (HSC, hematopoietic stem cells, TCDD, 2,3,7,8-tetrachlorodibenzo-.
Figure 1(A,B) Cxcr4 and Cxcl12 gene expression changes in primary rat BMSC grown in either standard or osteogenic media and treated with TCDD and dioxin-like compounds. (C) Chemotaxis rate of BMSC (toward 200 ng/mL of recombinant CXCL12) pretreated with TCDD and dioxin-like compounds. *p < 0.05 relative to DMSO vehicle control-treated cells. 2,3,7,8-TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; 1,2,3,7,8-PCDD, 1,2,3,7,8-pentachlorodibenzo-p-dioxin; 2,3,4,7,8-PCDD, 2,3,4,7,8-petachlorodibenzofuran; 2,3,7,8-TCDF, 2,3,7,8-tetrachlorodibenzofuran; PCB-126, 3,3′,4,4′,5-pentachlorobiphenyl; PCB-118, 2,3′,4,4′,5-pentachlorociphenyl; PCB-156, 2,3,3′,4,4′,5-hexachlorobiphenyl.
Environmental metals: chemokine changes.
| Substance | Chemokine(s) involved | Effect(s) | Cell/tissue type | Reference |
|---|---|---|---|---|
| Lead | ↓ | Beier et al. ( | ||
| Cadmium | CXCL1 | ↑ | Mouse RAW 264.7 Macrophages | Riemschneider et al. ( |
| CXCL8 | ↑ | Human THP-1 | Freitas and Fernandes ( | |
| Lithium | CXCL4 | ↑ | Human mesenchymal stem cell (MSC) | Satija et al. ( |
| CXCR12 | Human PBMC and PMN | Kim et al. ( | ||
| CXCL8 | ↓ | Human MSC | Satija et al. ( | |
| CCL20 | Human PBMC and PMN | Kim et al. ( | ||
| Strontium | CXCL8 | ↓ | Human primary monocytes | Buache et al. ( |
Known effects of environmental metals on chemokines.
Prosthetic wear particles: chemokine changes.
| Substance | Chemokine(s) involved | Effect(s) | Cell/tissue type | Reference |
|---|---|---|---|---|
| Cobalt | CXCL4 | ↑ | Human MG63 and SaOs-2 | Drynda et al. ( |
| CXCR12 | ||||
| CoNiCrMo alloy | ||||
| CoCrMo alloy | ||||
| Titanium | CXCR4 | Rat tibia tissue | Omar et al. ( | |
| CXCL8 | Human periprosthetic granuloma tissue | Nakashima et al. ( | ||
| CCL3 | ||||
| CCR4 | ↑ | Human fibroblasts | Trindade et al. ( | |
| CCL5 | Human MG63 | Fritz et al. ( | ||
| CCL17 | Mouse GE-1 and MC3T3-E1 | Wachi et al. ( | ||
Known effects of prosthetic wear particles on chemokines (Co, Cobalt; Ni, Nickel; Cr, Chromium; Mo, Molybdenum).